Therapy News and Research

RSS

Bortezomib reduces GVHD, boosts survival for patients receiving stem-cell transplants

Adding bortezomib (Velcade) to standard preventive therapy for graft-versus-host-disease (GVHD) results in improved outcomes for patients receiving stem-cell transplants from mismatched and unrelated donors, according to researchers from Dana-Farber Cancer Institute.

9 Dec 2013

Study helps explain why survival gap persists for African-Americans with head and neck cancer

A team of scientists at Johns Hopkins and in Texas has identified a handful of genetic mutations in black Americans, in addition to some chemical alterations affecting gene activity, which may help explain why the death rate among African-Americans from the most common form of head and neck cancer continues to hover some 18 percent higher above the death rate of whites with the same cancer.

9 Dec 2013

Gene discovered to play a part in one per cent of all cancers

Researchers have identified a gene that drives the development of tumours in over one per cent of all cancer patients. This is the first time that the gene CUX1 has been broadly linked to cancer development.

9 Dec 2013

Novel device may simplify monitoring of patients' response to treatment for ovarian cancer

A microchip-based device developed by Massachusetts General Hospital investigators may greatly simplify the monitoring of patients' response to treatment for ovarian cancer - the most lethal form of gynecologic cancer - and certain other malignancies.

6 Dec 2013

Auxilium Pharmaceuticals' XIAFLEX gets FDA approval for treatment of Peyronie's disease

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has approved XIAFLEX (collagenase clostridium histolyticum, or CCH), an in-office, biologic for the treatment of Peyronie's disease. XIAFLEX is the first and only FDA-approved treatment proven effective for PD in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy.

6 Dec 2013

ALS TDI forms research partnership with Neurimmune to advance potential treatments for ALS

The ALS Therapy Development Institute (ALS TDI), together with its wholly-owned subsidiary, Anelixis Therapeutics, announced today that it has formed a research partnership with Neurimmune to advance potential treatments for ALS, also known as Lou Gehrig's disease.

6 Dec 2013

New service helps hospitals and integrated delivery networks expand reach of outpatient pharmacies

At the annual Midyear Clinical Meeting of the American Society of Health-System Pharmacists (ASHP), Cardinal Health will launch a new service that helps hospitals and integrated delivery networks expand the reach of their outpatient pharmacies, while also generating additional revenue and freeing up pharmacist time to drive medication adherence and other quality measures.

6 Dec 2013

Study uncovers novel mechanism by which glioblastoma evades targeted therapies

A Ludwig Cancer Research study has uncovered an entirely novel mechanism by which glioblastoma, the most common kind of brain cancer, evades targeted therapies. Published in the current issue of the journal Science, the paper describes how GBM tumor cells essentially hide the signaling molecule targeted by such therapies, adding a layer of complexity to current models of drug resistance in cancer.

6 Dec 2013

Eli Lilly reports edivoxetine Phase III program did not meet primary endpoint for major depressive disorder

Eli Lilly and Company (NYSE: LLY) announced today that results from three studies of edivoxetine did not meet the primary study objective of superior efficacy in depression after eight weeks of treatment.

6 Dec 2013

Eisai reports new data analyses on FYCOMPA (Perampanel) at AES meeting

Today, Eisai Inc. announced that 16 abstracts highlighting new data analyses on FYCOMPA (perampanel) will be presented at the 67th annual American Epilepsy Society (AES) meeting, taking place in Washington, D.C. from December 6 – 10.

6 Dec 2013

INTENSIA family of ICDs and CRT-D devices receive CE mark approval

Sorin Group, a global medical company and a leader in the treatment of cardiovascular diseases, announced today that the INTENSIA family of implantable cardioverter defibrillators and cardiac resynchronization therapy devices received CE (Conformité Européenne) mark approval. This family of devices includes the single-chamber INTENSIA VR, the dual-chamber INTENSIA DR and the INTENSIA SonR® CRT-D devices, all of which feature a DF-4 high voltage connector.

6 Dec 2013

Researchers discover biological mechanism that allows brain tumor cells to escape from drugs

Researchers from UCLA's Jonsson Comprehensive Cancer Center have discovered a biological mechanism that allows brain tumor cells to escape from the drugs designed to target them, resulting in drug resistance. The study was published in the December 5, 2013 online issue of Science.

6 Dec 2013

Combination drug therapy does not work well in clinical trials for cancer patients, say researchers

Medical researchers at the University of Alberta have discovered that combination drug therapy didn't work well in clinical trials for cancer patients because one drug was making the other drug ineffective.

6 Dec 2013

Baylor researchers study outcomes and effectiveness of traumatic brain injury rehabilitation

For patients recovering from a traumatic brain injury (TBI), the rehabilitation process - compensating for changes in functioning, adaptation and even community reintegration - can be challenging.

6 Dec 2013

Study reveals that brain cancer cells resist therapy by dialing down gene mutation targeted by drugs

A team of scientists, led by principal investigator Paul S. Mischel, MD, a member of the Ludwig Institute for Cancer Research and professor in the Department of Pathology at the University of California, San Diego School of Medicine, has found that brain cancer cells resist therapy by dialing down the gene mutation targeted by drugs, then re-amplify that growth-promoting mutation after therapy has stopped.

6 Dec 2013

Researchers take closer look at genetically engineered mouse models and human cancer samples

Researchers from the Fred Hutchinson Cancer Research Center in Seattle, WA have taken a closer look at existing mouse models of cancer, specifically comparing them to human cancer samples. These genetically engineered mouse models (which usually either overexpress a cancer-causing gene-or "oncogene"-or carry a deletion for a "tumor suppressor" gene) have been extensively used to understand human cancer biology in studies of drug resistance, early detection, metastasis, and cancer prevention, as well as for the preclinical development of novel targeted therapeutics.

6 Dec 2013

Telomerase inhibiting drug induces morphologic, molecular, clinical remissions in myelofibrosis patients

metelstat, a novel telomerase inhibiting drug, has been found to induce morphologic, molecular and clinical remissions in some patients with myelofibrosis a Mayo Clinic study has found. The results were presented today at the 2013 American Society of Hematology Annual Meeting in New Orleans.

6 Dec 2013

Combination of preventive and therapeutic moxibustion has beneficial effect for Alzheimer's disease

An increasing number of clinical and animal studies have confirmed that acupuncture is effective for the treatment of Alzheimer's disease. Moxibustion is reported to be more effective than electro-acupuncture for improving space-recognizing memory ability in aged mice, suggesting that moxibustion is another alternative or complementary therapy used to treat Alzheimer's disease.

6 Dec 2013

Study results show insulin sensitizers reduce risk of cancer in female patients with type 2 diabetes

A Cleveland Clinic-led study shows that a specific type of diabetes drug can decrease the risk of cancer in female patients with type 2 diabetes by up to 32 percent.

5 Dec 2013

CEL-SCI gets approval to start enrollment for Multikine Phase III study for head and neck cancer

Further advancing one of the largest Phase III trials for head and neck cancer in the world, CEL-SCI Corporation announced today that it has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection).

5 Dec 2013

Therapy News and Research

Bortezomib reduces GVHD, boosts survival for patients receiving stem-cell transplants

Study helps explain why survival gap persists for African-Americans with head and neck cancer

Gene discovered to play a part in one per cent of all cancers

Novel device may simplify monitoring of patients' response to treatment for ovarian cancer

Auxilium Pharmaceuticals' XIAFLEX gets FDA approval for treatment of Peyronie's disease

ALS TDI forms research partnership with Neurimmune to advance potential treatments for ALS

New service helps hospitals and integrated delivery networks expand reach of outpatient pharmacies

Study uncovers novel mechanism by which glioblastoma evades targeted therapies

Eli Lilly reports edivoxetine Phase III program did not meet primary endpoint for major depressive disorder

Eisai reports new data analyses on FYCOMPA (Perampanel) at AES meeting

INTENSIA family of ICDs and CRT-D devices receive CE mark approval

Researchers discover biological mechanism that allows brain tumor cells to escape from drugs

Combination drug therapy does not work well in clinical trials for cancer patients, say researchers

Baylor researchers study outcomes and effectiveness of traumatic brain injury rehabilitation

Study reveals that brain cancer cells resist therapy by dialing down gene mutation targeted by drugs

Researchers take closer look at genetically engineered mouse models and human cancer samples

Telomerase inhibiting drug induces morphologic, molecular, clinical remissions in myelofibrosis patients

Combination of preventive and therapeutic moxibustion has beneficial effect for Alzheimer's disease

Study results show insulin sensitizers reduce risk of cancer in female patients with type 2 diabetes

CEL-SCI gets approval to start enrollment for Multikine Phase III study for head and neck cancer

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News